MedTrace Logo

Lisatoclax Plus R-CHOP or Pola-R-CHP in Untreated DLBCL: A Phase Ib/II Study

NCT07398638 · Status: NOT_YET_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 122

Last updated 2026-02-10

No results posted yet for this study

Summary

This is a prospective, multicenter, open-label Phase Ib/II clinical study designed to evaluate the safety, tolerability, preliminary efficacy, and pharmacokinetics of lisatoclax in combination with R-CHOP or Pola-R-CHP in patients with previously untreated diffuse large B-cell lymphoma (DLBCL).

Conditions

  • Diffuse Large B Cell Lymphoma (DLBCL)

Interventions

DRUG

R-CHOP

Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone

DRUG

POLA-R-CHP

Polatuzumab vedotin, Rituximab, Cyclophosphamide, Doxorubicin, Prednisone

DRUG

Lisaftoclax

Lisaftoclax (400 mg or 600 mg) is added from the second cycle of chemotherapy.

Sponsors & Collaborators

  • Sun Yat-sen University

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-02-28
Primary Completion
2029-02-28
Completion
2031-02-28

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07398638 on ClinicalTrials.gov